Two separate retraction items flagged publication integrity in medicine. BMJ Public Health retracted a controversial paper that alleged a link between COVID-19 vaccines and excess deaths after an institutional investigation concluded the findings could not stand. A separate notice also withdrew a British Journal of Cancer report describing GST-NT21MP’s antitumor activity in breast cancer via CXCR4 pathway inhibition. For the biotech industry, these actions matter because they can influence downstream research directions, trial rationales, and investigator interpretation of mechanistic claims. Retractions can also affect how companies validate targets or biomarkers that were tied to the retracted hypotheses. The events highlight the role of post-publication review and institutional processes in correcting the scientific record. From a risk-management perspective, teams increasingly need tighter controls around literature sourcing, especially when building translational or regulatory strategies off published preclinical claims.